Integral Health Asset Management LLC Makes New $13.40 Million Investment in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Integral Health Asset Management LLC acquired a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 420,000 shares of the company’s stock, valued at approximately $13,402,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Hudson Bay Capital Management LP raised its position in shares of Apellis Pharmaceuticals by 32.7% during the 4th quarter. Hudson Bay Capital Management LP now owns 345,000 shares of the company’s stock valued at $11,009,000 after acquiring an additional 85,000 shares during the last quarter. Gotham Asset Management LLC bought a new stake in shares of Apellis Pharmaceuticals during the 4th quarter valued at $775,000. Granahan Investment Management LLC raised its position in shares of Apellis Pharmaceuticals by 2.6% during the 4th quarter. Granahan Investment Management LLC now owns 154,418 shares of the company’s stock valued at $4,927,000 after acquiring an additional 3,840 shares during the last quarter. Focus Partners Wealth bought a new stake in shares of Apellis Pharmaceuticals during the 4th quarter valued at $320,000. Finally, Deutsche Bank AG raised its position in shares of Apellis Pharmaceuticals by 1.8% during the 4th quarter. Deutsche Bank AG now owns 1,778,377 shares of the company’s stock valued at $56,748,000 after acquiring an additional 30,867 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Insider Activity

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the transaction, the general counsel now owns 138,730 shares of the company’s stock, valued at $3,482,123. The trade was a 3.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 6,115 shares of company stock worth $154,684 in the last quarter. Corporate insiders own 6.50% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on APLS shares. The Goldman Sachs Group dropped their target price on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Bank of America cut shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $41.00 to $23.00 in a research report on Friday. Cantor Fitzgerald initiated coverage on shares of Apellis Pharmaceuticals in a research report on Tuesday, April 29th. They issued an “overweight” rating and a $44.00 price objective for the company. Needham & Company LLC lowered their price objective on shares of Apellis Pharmaceuticals from $40.00 to $29.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Finally, Wells Fargo & Company lowered their price objective on shares of Apellis Pharmaceuticals from $30.00 to $26.00 and set an “equal weight” rating for the company in a research report on Thursday. Nine equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Apellis Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $41.37.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ APLS opened at $17.30 on Monday. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -8.52 and a beta of 0.73. The business has a 50-day moving average of $21.15 and a 200-day moving average of $27.05. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.65 and a fifty-two week high of $43.99.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The company had revenue of $149.90 million during the quarter, compared to the consensus estimate of $197.61 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. Apellis Pharmaceuticals’s revenue was down 3.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.54) EPS. As a group, sell-side analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).